Hexaxim vaccine safety confirmed in 713 infants
NCT ID NCT06793826
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study checked the safety of the Hexaxim vaccine in 713 infants aged 2 months and older in South Korea. Researchers tracked side effects like injection site reactions, fever, and crying after routine vaccination. The goal was to confirm the vaccine's safety in everyday use, not to measure how well it prevents disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Hexaxim (a combined vaccine against diphtheria, tetanus, pertussis, polio, hepatitis B, and Haemophilus influenzae type b)
- What this could lead to
- If results are good, it confirms the vaccine's safety in routine use, supporting continued protection of infants from several serious diseases.
- What could go wrong
- This is a completed safety study, not a test of how well the vaccine works. It only looked for side effects, not effectiveness, and results may not apply to other countries or populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAEMOPHILUS INFLUENZAE TYPE B IMMUNISATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Investigational Site Number : 001
Seoul, South Korea
-
Investigational Site Number : 002
Cheonan, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple roadside test catch liver disease before it turns deadly?
- Hospital care model aims to treat opioid addiction and serious infections together
- Simple blood test aims to spot multiple cancers early
- Heart safety check for hepatitis b drug candidate
- Two-Drug combo aims to cure chronic hepatitis b
- Hepatitis b breakthrough? study checks if bepirovirsen response lasts